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Abstract
Introduction: TGF-b signaling has been extensively studied in many developmental contexts, amongst which is its
ability to induce epithelial to mesenchymal transitions (EMT). EMTs play crucial roles during embryonic
development and have also come under intense scrutiny as a mechanism through which breast cancers progress
to become metastatic. Interestingly, while the molecular hallmarks of EMT progression (loss of cell adhesion,
nuclear localization of b-catenin) are straightforward, the cellular signaling cascades that result in an EMT are
numerous and diverse. Furthermore, most studies describing the biological effects of TGF-b have been performed
using high concentrations of active, soluble TGF-b, despite the fact that TGF-b is produced and secreted as a latent
complex.
Methods: MCF-7 breast cancer cells treated with recombinant IGF-1 were assayed for metalloproteinase activity
and invasiveness through a matrigel coated transwell invasion chamber. IGF-1 treatments were then followed by
the addition of latent-TGF-b1 to determine if elevated levels of IGF-1 together with latent-TGF-b1 could cause EMT.
Results: Results showed that IGF-1 - a molecule known to be elevated in breast cancer is a regulator of matrix
metalloproteinase activity (MMP) and the invasive potential of MCF-7 breast cancer cells. The effects of IGF-1
appear to be mediated through signals transduced via the PI3K and MAPK pathways. In addition, increased IGF-1,
together with latent TGF-b1 and active MMPs result in EMT.
Conclusions: Taken together our data suggest a novel a link between IGF-1 levels, MMP activity, TGF-b signaling,
and EMT in breast cancer cells.
Introduction
Breast cancers, and indeed most cancers, usurp cellular
signaling pathways, particularly developmental pathways,
that are normally tightly regulated in the animal or
embryo. Alteration of these pathways often results in
oncogenic transformations. For example, in mammary
epithelial cells, a malignant phenotype is characterized
by increased proliferation, resistance to apoptosis and
metastasis. The transforming growth factor beta (TGF-
b) family of signaling molecules are key regulators of
both developmental, and malignant processes. Similarly,
insulin-like growth factor (IGF) signaling is also a hall-
mark for development and subsequent tissue homeosta-
sis [1]. IGF signaling is comprised of a dynamic network
of proteins including ligands (IGF-I and IGF-II), their
associated receptors, IGF-binding proteins (IGFBPs),
and IGFBP proteases [2,3]. Of particular interest, IGF-1
protein has been most strongly implicated in breast can-
cer progression because of its mitogenic and anti-apop-
totic effect on mammary epithelial cells [4]. IGF-I can
act in an endocrine, paracrine or autocrine manner.
Accordingly, IGF-1 levels and activity have been closely
examined in proliferative tissues for their relationship to
changes in cellular morphology associated with cancer
progression. Indeed there is a strong positive association
* Correspondence: sdamjano@uwo.ca
Department of Biology, University of Western Ontario, London, Ontario, N6A
5B7, Canada
Walsh and Damjanovski Cell Communication and Signaling 2011, 9:10
http://www.biosignaling.com/content/9/1/10
© 2011 Walsh and Damjanovski; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
between IGF-1 levels and breast cancer, especially
among premenopausal women [4].
Another potent signaling molecule that is correlated
with changes in cellular morphology and migration is
TGF-b. TGF-b is a secreted protein that exists in three
isoforms: TGF-b1, TGF–b2 and TGF-b3. Together these
proteins control many cellular processes including cellu-
lar proliferation, differentiation, and altered TGF-b sig-
naling has a significant role in a variety of diseases [5].
TGF-b signaling has been extensively studied in cancer
for its ability to induce epithelial to mesenchymal transi-
tions (EMTs) [6]. Amongst the common denominators
for an EMT are reduced cell adhesion, increased cell
migration and the nuclear localization of b-catenin [7,8].
Though EMTs are primarily a mechanism for tissue pat-
terning during development, this cellular process has
also been observed in adult tissue as an explanation for
the conversion of various epithelial cells to a mesenchy-
mal, and ultimately metastatic phenotype. While many
studies have investigated TGF-b’s role in regulating
EMTs, most studies describing biological effects of
TGF-b have been carried out in vitro using high con-
centrations of active, soluble TGF-b, despite the fact
that TGF-b is produced and secreted in vivo as a latent
complex [9]. While much is known about TGF-b signal-
ing in comparison, the mechanism of TGF-b activation,
and its relationship to IGF-1 in breast cancer metastasis,
is poorly understood.
IGF family molecules bind to a variety of insulin-like
growth factor receptors (IGFRs). These receptors are
receptor tyrosine kinases (RTKs) and most frequently
signal through PI3K and MAPK dependent mechanisms
[10]. Conversely, TGF-b receptors are serine/threonine
kinases that typically signal through SMAD 2/3 depen-
dent mechanisms [11]. Of particular interest, TGF-b is
secreted as a preproprotein and is part of an inactive
complex. This complex consists of the TGF-b, a propep-
tide latency-associated peptide (LAP), and a latent TGF-
b binding protein (LTBP). Once secreted this complex
can then be linked to components of the extracellular
matrix (ECM). Typically the majority of extracellular
TGF-b is inactive. Only upon the activation of this
latent complex is a mature active dimeric TGF-b pep-
tide released. Several means of TGF-b activation have
been elucidated, but all involve the proteolytic degrada-
tion of LAP, with plasmin and MMPs proving to be
important players in the degradation of LAP and the
release of mature TGF-b. Interestingly, however, binding
of LAP to integrins or other ECM proteins such as
thrombospondin, can cause a conformational change in
LAP and also result in the subsequent release of active
TGF-b, which is then free to bind to its receptor [12,13].
In this study we look at the effects of both IGF-1 sti-
mulation, and increased latent TGF-b1 levels, on MCF-7
breast cancer cells to see if these proteins may work in
conjunction to alter cellular morphology and increase
the invasive potential of these cells. Here we demon-
strate a novel link between IGF-1 signaling, MMP acti-
vation and TGF-b signaling, and propose a novel
mechanism for EMT induction in MCF-7 cells.
Results
IGF-1 regulated metalloproteinase activity in MCF-7
breast cancer cells via the PI3K and MAPK pathways
IGF-1 has been shown previously to stimulate protease
activity in many cell types [13]. To determine if IGF-1
could stimulate metalloproteinase activity in MCF-7
cells they were treated with 100 nM recombinant IGF-1,
and subsequently their conditioned media was used to
assay for metalloproteinase activity using a broad-spec-
trum metalloproteinase (Mca-KPLGL-Dpa-AR-NH2)
Fluorogenic Peptide Substrate. IGF-1 treatment resulted
in a 2.9 fold increase in metalloproteinase activity com-
pared to vehicle control (Figure 1a). To identify the
pathway(s) regulating protease induction by IGF-I, phar-
macological inhibitors were used that inhibit Phosphoi-
nositide 3-kinases (PI3K) and Mitogen-Activated Protein
Kinase (MAPK) signaling - two known downstream
IGF-I effectors [13]. Treatment with the PI3K inhibitor
wortmannin (5 nm) significantly reduced IGF-I-
mediated protease activation by 34% (Figure 1a). Treat-
ment with the MAPK inhibitor SB 202190 (10 M) had a
29% decrease in IGF-1 induced protease activation (Fig-
ure 1a). Cell viability was unaltered by treatments (Fig-
ure 1b) confirming that the effects of the inhibitors
were not due to alterations in cell viability. The specifi-
city of the reagents on mediating cellular events and not
simply altering activity in the culture media was assayed
via the addition of the above reagents to cell free condi-
tioned media where in resulted in no significant changes
in MMP activity (Figure 1c). Western Blot analysis of
MCF-7 cells treated with MAPK or PI3K inhibitors
revealed decreased levels of phospho-ERK and phospho-
AKT moieties respectively, confirming the efficacy of
the inhibitors (Figure 1d-e). Notably, the treatment of
MCF-7 cells with IGF-1 increased invasiveness through
a matrigel coated transwell invasion chamber by ~400%
compared to control (Figure 1f). Pre-treatment of cells
with PI3K or MAPK inhibitors before IGF-1 treatment
resulted in no significant change in invasiveness com-
pared to control (Figure 1f).
IGF-1 with latent TGF-b1 caused morphological changes
in MCF-7 cells consistent with EMT
Recent evidence suggested that signaling after the pro-
teolytic activation of latent TGF-b1 could induce EMT
in breast cancer leading to metastasis [14]. There is also
a strong correlation between high levels of IGF-1
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signaling and metastasis [15]. The link between IGF-1
and TGFb1 signaling however, has not thoroughly been
explored. Here we show that treating MCF-7 cells first
with IGF-1 (8 h), and then subsequently with latent
TGF-b1 (48 h) resulted in a change to a cellular fibro-
blast-like morphology consistent with EMT (Figure 2g).
MCF-7 vehicle treatment (control), or treatment with
IGF-1 or latent TGF-b1 alone did not induce this
change in cellular morphology (Figure 2a, c, e). Further-
more, pretreatment of cells with PI3K or MAPK inhibi-
tors demonstrated the specificity of these pathways in
IGF-1 mediated latent TGF-b1 induced morphological
changes as it prevented changes in morphology (Figure
2d, f). TGF-b1 specificity is highlighted by the addition
of TGF-b inhibitor that blocked changes in morphology
after IGF-1+latent TGF-b1 treatment (Figure 2h). Inhi-
bition of matrix metalloproteinase’s using BB94 also
abolished IGF-1 mediated, latent TGF-b1 signals, as
cells retained epithelial morphology (Figure 2b). These
findings indicated that IGF-1 treatment may have played
a role in promoting the activation of latent TGF-b1
leading to EMT.
Figure 1 IGF-1 increased metalloproteinase activity and invasiveness in MCF-7 breast cancer cells via the PI3K and MAPK pathways. a)
Treatment of MCF-7 cells with 100 nM recombinant IGF-1 caused a 2.9 fold increase in protease activity as determined using a fluoregenic
metalloproteinase substrate. Pretreatment of cells with PI3K or MAPK inhibitors attenuated the increased protease activation and resulted in a
34% and 29% decrease in activity respectively compared to IGF-1 treatment alone. b) MCF-7 cell viability, assessed by a fluorogenic viability
assay, was not significantly affected by IGF-1 and/or inhibitor treatments. c) Treatment of MCF-7 conditioned media with aforementioned
reagents resulted in no significant changes in MMP activity. d-e) Western Blot analysis of MCF-7 cells treated with MAPK or PI3K inhibitors reveals
decreased expression of phospho-ERK and phospho-AKT expression respectively. f) Treatment of MCF-7 cells with 100 nM recombinant IGF-1
increased invasiveness through a matrigel coated transwell chamber by ~400% compared to vehicle treatment (control). Pre-treatment of cells
with PI3K or MAPK inhibitors before IGF-1 treatment resulted in no significant change in invasiveness compared to vehicle control. Each assay
was repeated three times (three experimental repeats). All data are mean ± s.e.m, (n = 3) *P < 0.01.
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Figure 2 IGF-1 and latent TGF-b1 caused morphological changes in MCF-7 cells consistent with EMT. Vehicle treated cells showed typical
rounded epithelial morphology (a). Treatment of MCF-7 cells with 100 nM recombinant IGF-1 + 10 nM latent TGF-b1 caused a mesenchymal
morphological phenotype characterized by a fibroblast-like appearance (g). Treatment with IGF-1 or latent TGF-b1 alone did not result in a
morphological change (c, e). Pre-treatment of cells with PI3K or MAPK inhibitors abolished IGF-1 + latent TGF-b1 induced mesenchymal
morphological phenotype (d, f). BB94 or TGF-b1 inhibitor prevented the morphological changes associated with IGF-1 + TGF-b1 treatment (b, h).
Cytoskeleton was stained with phalloidin (red) and the nucleus with DAPI (blue). Images are representative of 3 independent experiments with
consistent results.
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IGF-1 with latent TGF-b1 resulted in changes in marker
gene expression consistent with EMT
To investigate if the IGF-1 and latent TGF-b1 induced
changes in morphology were consistent with changes in
expression of EMT marker genes, real-time PCR was
performed with primers for E-cadherin, N-cadherin,
occludin and vimentin. Treatment with latent TGF-b1
alone did not promote significant changes in marker
gene expression compared to vehicle treatment (control
-data not shown). Expression levels after latent TGF-b1
treatments were therefore used for comparisons with
other treatments. MCF-7 cells treated with IGF-1 +
latent TGF-b1 showed ~24 and ~8 fold increases in
mesenchymal markers N-cadherin and vimentin respec-
tively, and ~21 and ~6 fold decreases in epithelial mar-
kers E-cadherin and occludin respectively compared to
cells treated with latent TGF-b1 alone (Figure 3). This
expression pattern is consistent with EMT seen in other
cell types [16]. Pretreatment of cells with PI3K or
MAPK inhibitors attenuated the IGF-1 + latent TGF-b1
mediated changes in EMT marker gene expression (Fig-
ure 3). IGF-1 treatment alone increased vimentin, but
this in itself is not indicative of EMT. MCF-7 cells trea-
ted with a TGF-b1 inhibitor or the MMP inhibitor BB94
also did not show changes in marker gene expression
consistent with EMT.
Figure 3 Semi-quantitative real time PCR showed IGF-1 and latent TGF-b1 resulted in changes in marker gene expression consistent
with EMT in MCF-7 cells. MCF-7 cells treated with (i) IGF-1, (ii) IGF-1+latent TGF-b1, (iii) IGF-1+latent TGF-b1+PI3K inhibitor, (iv) IGF-1+latent
TGF-b1+MAPK inhibitor, (v) IGF-1atent TGF-b1+TGF-b1 inhibitor or (vi) IGF-1+latent TGF-b1+MMP inhibitor were analyzed for levels of marker
genes associated with EMT. E-cadherin, and occludin levels decreased by 21 and 6 fold respectively while N-cadherin and vimentin levels
increased by 24 and 8 fold respectively when treated with IGF1-+ latent TGF-b1 as compared to latent TGF-b1 treatment alone. As there was no
significant difference between vehicle and latent TGF-b1 treatment, latent TGF-b1 treatment alone was used for comparison with other
treatments to further highlight changes associates with the activation of TGF-b1 and EMT. The addition of PI3K, MAPK, MMP or TGF-b1 inhibitors
attenuated these changes in marker gene expression. With the exception of vimentin, IGF-1 treatment alone caused changes in marker gene
expression similar to that seen with IGF-1+ TGF-b1+inhibitors. All data are mean ± s.e.m. (n = 3, three experimental repeats).
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To investigate the specificity of the IGF-1/latent TGF-
b treatments in modulating EMT specific cellular events,
a cell line that could not undergo an EMT was also
used. In contrast to MCF-7 cells, Hs578t breast cancer
cells are highly invasive atypical epithelial cells, do not
express E-cadherin, and already have a mesenchymal
morphology. Although treatment of Hs578t cells with
IGF-1 and/or latent TGF-b1 resulted in minor altera-
tions of EMT marker gene expression, there were no
significant changes in multiple marker genes that would
be consistent with, and indicative of an EMT signature
(Figure 4) [17].
IGF-1 with latent TGF-b1 resulted in nuclear localization
of b-catenin in MCF-7 cells
There have been many contradictory studies regarding
the induction of the b-catenin/TCF pathway by IGF
[18]. Playford et al., reported that IGF alone could not
induce b-catenin/TCF-dependent transcriptional activa-
tion whereas other researchers have reported it can.
Since activation of this pathway and the subsequent
nuclear localization of b-catenin is a hallmark of EMT,
we chose to look at the nuclear localization of b-catenin
after IGF-1 and latent TGF-b1 treatment of MCF-7
breast cancer cells. IGF-1 + latent TGF-b1 treatment of
MCF-7 cells resulted in nuclear localization of b-catenin
(Figure 5g, h). Vehicle (control), IGF-1 or TGF-b1 alone
did not cause nuclear localization of b-catenin as the b-
catenin signal was still prevalent at the plasma mem-
brane (Figure 5a-f).
Discussion
The extensive array of cytokines and growth factors
sequestered by the ECM can regulate cell proliferation,
differentiation and migration [19]. Accordingly, the
importance of maintaining homeostasis within the ECM
microenvironment has been widely recognized and the
significance of ECM remodeling has recently become
the focus of intense scientific research. The diversity of
the ECM underlies its function as a structural element
and as a contributor to tissue development and physiol-
ogy [20]. MMPs are a family of highly homologous
endopeptidases that cleave and remodel the extracellular
matrix (ECM) [21]. Currently, there are 24 known
MMPs that collectively have the potential to cleave and
remodel all major ECM constituents. Considering the
range of effects that MMPs and ECM remodeling can
have on cell physiology, it is not surprising that MMPs
activity has been associated with many diseases and
pathological conditions including the metastatic poten-
tial of many types of cancer [22].
Here we demonstrate that IGF-1 plays a role in the
activation of MMPs and causes increased invasive
potential in breast cancer cells. Specifically we show that
Figure 4 Semi-quantitative real time PCR showed IGF-1 and
latent TGF-b1 resulted in no changes in EMT marker gene
expression consistent with EMT in Hs578t cells. Hs578t cells
treated with (i) IGF-1, (ii) IGF-1+latent TGF-b1, (iii) IGF-1+latent TGF-
b1+PI3K inhibitor, (iv) IGF-1+latent TGF-b1+MAPK inhibitor or (v)
IGF-1+latent TGF-b1+TGF-b1 inhibitor were analyzed for levels of
marker genes associated with EMT. Changes in N-cadherin, occludin,
and vimentin expression were not consistent with EMT after
treatment with IGF-1+TGF-b1 compared to TGF-b1 treatment alone.
The addition of PI3K. MAPK or TGF-b1 inhibitors did not affect these
changes in marker gene expression. Hs578t cells treated with TGF-
b1 alone resulted in changes in marker gene expression that were
also not consistent with EMT compared to vehicle control. All data
are mean ± s.e.m. (n = 3, three experimental repeats).
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IGF-1 increases the proteolytic activity and invasive
potential of MCF-7 cells. Mca-KPLGL-Dpa-AR-NH2 is
a fluorogenic peptide substrate that is a highly specific
target for many MMPs including: MMP-1 (collagenase
1), MMP-2 (gelatinase A), MMP-7 (matrilysin), and
MMP-9 (gelatinase B). The use of this peptide
demonstrated that the addition of IGF-1 alone increased
MMP activity.
Inhibition of either the PI3K or MAPK pathways illu-
strated the specificity of this IGF-1 mediated increase in
MMP activity. It has been previously shown that both
PI3K and MAPK pathways are activated by IGF-1 to
Figure 5 IGF-1 and latent TGF-b1 resulted in nuclear localization of b-catenin in MCF-7 cells. Nuclei are stained with DAPI (blue) while b-
catenin is localized with a specific antibody (green). Treatment of MCF-7 cells with 100 nM recombinant IGF-1 + 10 nM TGF-b1 resulted in
nuclear (blue) localization of b-catenin (green) (green blue overlap g-h). Treatment with vehicle control (a-b), IGF-1 (c-d) or TGF-b1 alone (e-f)
showed b-catenin primarily localized at the plasma membrane. Images are representative of 3 independent experiments with consistent results.
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promote cell survival, but to our knowledge, it has never
been shown that IGF-1 activates MMPs in a breast can-
cer cell line and that this, in part, functions via the PI3K
and MAPK pathways.
Although IGF-1 signaling in breast cancer has been
primarily associated with paracrine activity, endocrine
sources of IGF-1 may also have a role in breast cancer.
Circulating IGF-1 levels are higher in breast cancer
patients compared with normal controls [23]. Breast
cancer cells, as with most embryonic cells, are known to
respond to many stimuli, including growth factors and
cytokines that are housed in the ECM. The release of
such factors could thus trigger the cells to proliferate or
change their morphology, and in the case of breast can-
cers, metastasize. As a principal feature of breast cancer
is uncontrolled proliferation, identifying and under-
standing the regulatory molecules and pathways that
govern these cells is essential. Here we show that IGF-1
activates matrix metalloproteinase that have the poten-
tial to cleave the ECM and may release potent bioactive
molecules leading to possible growth, proliferation and
metastasis of a primary tumor. This reiterates the
importance of IGF-1 mediated protease activation, and
the downstream consequences of increased IGF-1 sig-
naling in cell migration, invasion, and breast cancer.
A major conclusion from our study is that IGF-1 sig-
naling and TGF-b signaling work in concert to bring
about an epithelial to mesenchymal transition in MCF-7
cells. TGF-b signaling has been widely studied in cancer
for its ability to induce EMTs leading to metastasis [24].
Most studies describing the biological effects of TGF-b
have been carried out in vitro using high concentrations
of active, soluble TGF-b, despite the fact that TGF-b is
produced and secreted in vivo as a latent complex [8].
Thus the conditions for the activation of TGF-b are not
addressed. In addition, although both IGF-1 levels and
TGF-b signaling are associated with the metastatic
potential of breast cancer, the mechanism of TGF-b
activation and its effect on cell invasion is still poorly
understood. Here for the first time we establish a critical
link between these two pathways and their contribution
to cancer progression. Based on our findings in MCF-7
cells, we present a model of putative latent TGF-b1 acti-
vation (Figure 6). We propose that IGF-1 transmits sig-
nals via both the PI3K and MAPK pathways that cause
the transcription of unknown but specific genes. These
gene products result in the extracellular activation of
MMPs. This MMP activation is IGF-1 dependent and
attenuated if the PI3K or MAPK signals are blocked.
MMPs are then capable of working in the ECM to acti-
vate latent TGF-b1. Active TGF-b1 results in EMT
characterized by the nuclear localization of b-catenin,
changes in morphology and the transcription of EMT
marker genes. The addition of a TGF-b inhibitor blocks
this signaling cascade, demonstrating the specificity of
TGF-b1 signaling. While our finding are based on stu-
dies using MCF-7 cells, the pathways and molecules
examined are globally used in many cell types, develop-
mental processes and diseases, and as such we believe
that our model has broad relevance.
Latent TGF-b activation has been described as a com-
plex multistep process[21,25]. TGF-b maturation is
highly controlled in order to regulate the formation of
active TGF-b. Although there has been significant pro-
gress in elucidating the components and mode of TGF-
b secretion, little is known about the fate of latent TGF-
b after its association with the ECM, nor the final steps
of TGF-b activation. Various evidence for latent TGF-b
activation suggests its cleavage, and subsequent activa-
tion, is mediated by plasmin. The formation of active
TGF-b has been shown to be blocked by plasmin inhibi-
tors or by depletion of plasminogen [7]. Here we show a
novel mechanism for TGF-b signaling via IGF-1
mediated activation of MMPs, as latent TGF-b1 activity
Figure 6 Schematic Model of IGF-1 and TGF-b1 signaling in
MCF-7 breast cancer cells. 1) IGF-1 binds IGF-1 receptor. 2) IGF-1
receptor signals through the PI3K and MAPK pathways. 3) IGF-1
signaling causes transcriptional activation of unknown target genes
(?). 4) Unknown target protein(s) (?) are secreted and activate MMPs.
5) Active MMPs are available to activate latent molecules in the
ECM, such as TGF-b. 6) Active TGF-b1 binds TGF-b1 receptor. 7)
TGF-b signaling causes nuclear localization of b-catenin. 8) TGF-b
signaling causing transcriptional activation of genes that result in an
EMT.
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is blocked by an MMP inhibitor. Interestingly, there is a
strong positive correlation between MMP activity and
the levels of plasmin, as plasmin is a post-translational
activator of MMPs [25]. Perhaps in previous studies the
depletion of plasmin also may have resulted in
decreased activation of MMPs, which in turn may have
contributed to the decreased activation of latent TGF-b
(a hypothesis that we will test at a later date).
Conclusions
Here we demonstrate a novel link between 2 hallmark
signaling pathways associated with the migratory and
invasive potential of cells. IGF-1 signaling ultimately
induces the activation of latent TGF-b1 leading to EMT
in a breast cancer cell line. Furthermore, consistent with
IGF-1 mediated invasiveness, inhibition of the PI3K or
MAPK pathway attenuates this IGF-1 mediated TGF-b1
signaling. This study gives further insight into the speci-
fic pathways that are required for latent TGF-b activa-
tion and highlights the importance of IGF-1 levels and
TGF-b activity in cells, particularly breast cancer cells.
Further experiments are required to elucidate the addi-
tional elements and the complete mechanism for IGF-1
signaling and TGF-b1 induction pathways and to con-
firm that these mechanisms are pertinent in other cell
lines, disease and developmental pathways.
Materials and methods
Cell culture and treatments
The MCF-7 and Hs578t cell lines were obtained from
the American Type Culture Collection (Manassas, VA)
and cultured in Dulbecco’s modified eagle’s medium
(DMEM-F12; Invitrogen Canada Inc.) supplemented
with 10% fetal bovine serum (FBS; Invitrogen Canada
Inc.) 50 g/ml penicillin and 50 g/ml streptomycin (Invi-
trogen Canada Inc.). All cells serum starved in DMEM-
F12 for 24 h prior to treatments. IGF-1 (R&D Systems
Inc.) was used to treat cells at 100 nM. Latent TGF-b1
(R&D Systems Inc.) was used at 10 nM. Inhibitors used
were; PI3K inhibitor Wortmannin -100 nM, p38/MAPK
inhibitor SB 202190 - 25 M, TGFbR1 kinase inhibitor
SD 208 - 1 M (Sigma-Aldrich), MMP inhibitor BB94 -
60 nM (Tocris Biosciences). MCF-7 cells were pre-
treated with pharmacological inhibitors for 30 minutes
prior to the addition of IGF-1. Latent TGF-b1 was
added 8 h (to allow sufficient time for products of IGF-
1 signaling to be translated) after the addition of IGF-1.
Cells were then incubated for 48 hours prior to b-cate-
nin localization, viability, PCR, and morphology assays.
Vehicle treatments were a combination of 1× Phosphate
Buffered Saline (IGF-1 vehicle) and dimethyl sulfoxide
(pharmological inhibitor vehicle). Viability of cells was
assessed using a DHL™ Cell Viability and Proliferation
Assay Kit (Anaspec) as per manufacturer’s instructions.
Cell viability was quantified by measuring fluorescence
with an excitation at 590 nm and emission at 530 nm
using a Molecular Devices M2E microplate reader.
MMP Activity Assay
MCF-7 cells were treated with vehicle (control), IGF-1
or IGF-1 after pretreatment with MAPK or PI3K inhibi-
tors for 30 mins. Eight hours after the addition of IGF-
1, MMP activity was assayed in the conditioned media.
One hundred microlitres of conditioned media was
added to 10 M Mca-KPLGL-Dpa-AR-NH2 -a broad
spectrum MMP fluorogenic peptide substrate and incu-
bated for 2 h at 37°C (R&D Systems Inc., Minneapolis,
MN). As a control, conditioned media from untreated
MCF-7 cells was spiked with IGF-1, IGF-1+MAPK, or
IGF-1+PI3K inhibitors. Enzymatic activity was measured
using a SpectraMax M2 microplate reader (Molecular
Devices) and SoftMax Pro v5 software with excitation at
320 nm and emission at 405 nm.
RNA Isolation
48 h after treatment, total RNA from MCF-7 cells was
extracted using an RNAeasy mini kit (Qiagen) according
to the manufacturer’s instructions. The integrity and pur-
ity of the total RNA were checked using gel electrophor-
esis and a NanoVue Spectrophotometer (GE Healthcare).
Western Blot Analysis
MCF-7 cells were treated for 1 h with MAPK or PI3K
inhibitors and then protein was isolated from cells using
M-PER Mammalian Protein Extraction Buffer (Thermo
Scientific). Samples were resolved using a 10% polyacry-
lamide gel and transferred to a Millipore Immobilon-FL
polyvinylidene difluoride membranes (Millipore). Mem-
branes were then blocked in Odyssey Blocking Buffer
(OBB, LI-COR Biosciences) for 1 h at RT. Samples were
then incubated for 16 h at 4°C with appropriate antibo-
dies: anti-ERK (1:500 Cell Signaling), anti-phospho ERK
(1:500 Cell Signaling), anti-AKT (1:500 Cell Signaling),
anti-phospho AKT (1:500 Cell Signaling) and GAPDH
(1:20000 Cell Signaling). Membranes were washed and
incubated wit appropriate secondary antibody for 1 h at
room temperature. Bands of immunoreactivity were
visualized and images captured using an Odyssey 2.1
scanner (LI-COR Biosciences).
Synthesis of Complementary DNA and Quantitative (real-
time) PCR
Complementary DNA (cDNA) was synthesized using
qScript™ cDNA SuperMix (Quanta BioSciences). Q-
PCR was performed using the CFX96™ Real-Time PCR
Detection System (Bio-Rad) in a two-step procedure
using PerfeCTa¨ SYBR¨ Green SuperMix (Quanta Bios-
ciences). Amplification of glyceraldehydes-3-phosphate
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dehydrogenase (GAPDH) was performed to standardize
the amount of sample cDNA. Primer sequences were as
follows: GAPDH (forward) 5’tcggtgtgaacggatttg, (reverse)
5’ggtctcgctcctggaaga;




Vimentin (forward) 5’ctggatttcctcttcgtgga, (reverse)
5’cgaaaacaccctgcaatctt;
Occludin (forward) 5’atgccatgggactgtcaact, (reverse)
5’tttgtgggacaaggacaca.
All reactions were performed in a 96 well plate using
the following cycling conditions: 40 cycles of 95°C for
15s, and 60°C for 30 s, 72°C 1 min. Using the CT
(delta-delta CT) method, the value of each control sam-
ple was set at 1 and used to calculate the fold-change of
target genes. When comparing gene expression profiles
between vehicle control and latent TGF-b treatment, we
found no significant changes associated with EMT;
accordingly, we normalized all other treatment condi-
tions to latent TGF-b treatment in order to highlight
the importance of TGF-b activation.
Immunofluorescence
All cells were grown on glass coverslips pretreated with
1 mg/ml Poly-Lysine. After treatment cells were fixed
with 4% paraformaldehyde for 10 mins and then rinsed
three times with phosphate-buffered saline (PBS) at
room temperature. For morphological analysis, cells
were permeablized with 0.1% Triton-X 100 and stained
with Alexa Fluor 633 phalloidin (1:33 dilution) for 20
mins and 4’,6-diamidino-2-phenylindole (DAPI) for 5
mins. For b-catenin localization, after blocking with 10%
normal goat serum (Gibco) for 1 h at room temperature,
cells were incubated with rabbit polyclonal b-catenin
antibody (1:100 dilution; Sigma-Aldrich) at room tem-
perature for 2 h, washed three times with PBS, and
incubated with Alexa Fluor 488 labelled goat anti-rabbit
secondary antibody (1:200 dilution; Molecular Probes)
for 1 h. The cells were then washed with PBS and coun-
terstained with 4’,6-diamidino-2-phenylindole (DAPI)
for 10 mins. Cells were all mouted using ProLong¨ Gold
antifade reagent (Invitrogen). Images were taken using a
Zeiss Z1 Microscope, AxioVision MRm camera and
AxioVision 4.8 software. Lenses used were a Zeiss 63×
oil immersion 1.4NA and a Zeiss 20× 0.5NA. Images
were taken at 23°C at the Integrated Microscopy @ Bio-
tron - University of Western Ontario.
Matrigel Invasion Assay
Eight hours after treatments, one hundred thousand
cells were added per transwell invasion chamber coated
with 1-2 mg/ml Matrigel (reconstituted basement
membrane; BD Biosciences, Mississauga, ON). Cells
were allowed to invade for 24 h. Cells were fixed for 30
mins in methanol, stained for 30 mins with 1% crystal
violet and the number of invaded cells were counted per
field of view at 20× magnification.
Statistical Analysis
Statistical significance was determined using Tukey’s
Post Hoc Test based on 3 independent experiments.
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